Harm-Jan de Grooth1, Wai-Ping Manubulu-Choo2, Anthe S Zandvliet3, Angélique M E Spoelstra-de Man4, Armand R Girbes4, Eleonora L Swart3, Heleen M Oudemans-van Straaten4. 1. Department of Intensive Care, VU University Medical Center, Amsterdam, The Netherlands; Department of Anesthesiology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: h.degrooth@vumc.nl. 2. Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands; Department of Pharmacy, Westfriesgasthuis, Hoorn, The Netherlands. 3. Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Intensive Care, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Early high-dose IV vitamin C is being investigated as adjuvant therapy in patients who are critically ill, but the optimal dose and infusion method are unclear. The primary aim of this study was to describe the dose-plasma concentration relationship and safety of four different dosing regimens. METHODS: This was a four-group randomized pharmacokinetic trial. Patients who were critically ill with multiple organ dysfunction were randomized to receive 2 or 10 g/d vitamin C as a twice daily bolus infusion or continuous infusion for 48 h. End points were plasma vitamin C concentrations during 96 h, 12-h urine excretion of vitamin C, and oxalate excretion and base excess. A population pharmacokinetic model was developed using NONMEM. RESULTS:Twenty patients were included. A two-compartment pharmacokinetic model with creatinine clearance and weight as independent covariates described all four regimens best. With 2 g/d bolus, plasma vitamin C concentrations at 1 h were 29 to 50 mg/L and trough concentrations were 5.6 to 16 mg/L. With 2 g/d continuous, steady-state concentrations were 7 to 37 mg/L at 48 h. With 10 g/d bolus, 1-h concentrations were 186 to 244 mg/L and trough concentrations were 14 to 55 mg/L. With 10 g/d continuous, steady-state concentrations were 40 to 295 mg/L at 48 h. Oxalate excretion and base excess were increased in the 10 g/d dose. Forty-eight hours after discontinuation, plasma concentrations declined to hypovitaminosis levels in 15% of patients. CONCLUSIONS: The 2 g/d dose was associated with normal plasma concentrations, and the 10 g/d dose was associated with supranormal plasma concentrations, increased oxalate excretion, and metabolic alkalosis. Sustained therapy is needed to prevent hypovitaminosis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02455180; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: Early high-dose IV vitamin C is being investigated as adjuvant therapy in patients who are critically ill, but the optimal dose and infusion method are unclear. The primary aim of this study was to describe the dose-plasma concentration relationship and safety of four different dosing regimens. METHODS: This was a four-group randomized pharmacokinetic trial. Patients who were critically ill with multiple organ dysfunction were randomized to receive 2 or 10 g/d vitamin C as a twice daily bolus infusion or continuous infusion for 48 h. End points were plasma vitamin C concentrations during 96 h, 12-h urine excretion of vitamin C, and oxalate excretion and base excess. A population pharmacokinetic model was developed using NONMEM. RESULTS: Twenty patients were included. A two-compartment pharmacokinetic model with creatinine clearance and weight as independent covariates described all four regimens best. With 2 g/d bolus, plasma vitamin C concentrations at 1 h were 29 to 50 mg/L and trough concentrations were 5.6 to 16 mg/L. With 2 g/d continuous, steady-state concentrations were 7 to 37 mg/L at 48 h. With 10 g/d bolus, 1-h concentrations were 186 to 244 mg/L and trough concentrations were 14 to 55 mg/L. With 10 g/d continuous, steady-state concentrations were 40 to 295 mg/L at 48 h. Oxalate excretion and base excess were increased in the 10 g/d dose. Forty-eight hours after discontinuation, plasma concentrations declined to hypovitaminosis levels in 15% of patients. CONCLUSIONS: The 2 g/d dose was associated with normal plasma concentrations, and the 10 g/d dose was associated with supranormal plasma concentrations, increased oxalate excretion, and metabolic alkalosis. Sustained therapy is needed to prevent hypovitaminosis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02455180; URL: www.clinicaltrials.gov.
Authors: Ping Tong; Fu-Rong Huang; Jun Xu; Zi-Qi Wu; Xing Hu; Ming Ling; Die Wang; Bu-Fei Wu; Du-Jiao Yang; Ai-Min Zhang Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2022-06-15
Authors: Stefan W Leichtle; Anand K Sarma; Micheal Strein; Vishal Yajnik; Dennis Rivet; Adam Sima; Gretchen M Brophy Journal: Neurocrit Care Date: 2020-02 Impact factor: 3.210
Authors: Ata Mahmoodpoor; Kamran Shadvar; Sarvin Sanaie; Mir Reza Hadipoor; Mohammad Ata Pourmoghaddam; Seied Hadi Saghaleini Journal: BMC Infect Dis Date: 2021-06-29 Impact factor: 3.090